Chemotherapy News and Research

Latest Chemotherapy News and Research

Polaris Group reports positive results from ADI-PEG 20 Phase 2 trial for malignant pleural mesothelioma

Polaris Group announced today that positive results from a randomized Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of malignant pleural mesothelioma were presented at the World Conference on Lung Cancer in Sydney, Australia.

28 Oct 2013

Biodesix presents additional VeriStrat Phase III trial data at World Conference on Lung Cancer

Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced additional data from the Phase III clinical trial for its serum protein test, VeriStrat. Results were presented at the 15th World Conference on Lung Cancer in Sydney, Australia.

28 Oct 2013

Research: Neurotoxin provides more relief from pain in dogs with bone cancer

By the time bone cancer is diagnosed in a pet dog, it is often too late to save the animal's life. Instead, the goal of treatment is to keep the dog as comfortable and free of pain as possible for as long as possible.

25 Oct 2013

MIT researchers design stealth drug delivery system to attack TNBC cells

Some of the most dangerous cancers are those that can outmaneuver the very drugs designed to defeat them, but researchers are now reporting a new Trojan-horse approach. In a preliminary study in the journal ACS Nano focusing on a type of breast cancer that is highly resistant to current therapies, they describe a way to sneak small particles into tumor cells, lower their defenses and attack them with drugs, potentially making the therapy much more effective.

25 Oct 2013

Diabetic patients may require higher doses of metformin to achieve same anti-cancer activity

A University of Colorado Cancer Center study published online this month in the journal Cell Cycle shows that breast cancer cell growth, motility and aggression is promoted by excess glucose, as experienced by patients with diabetes and metabolic syndrome.

25 Oct 2013

"One-two punch" disables tumors' defenses

An aggressive form of breast cancer known as "triple negative" is very difficult to treat: Chemotherapy can shrink such tumors for a while, but in many patients they grow back and gain resistance to the original drugs.

25 Oct 2013

Pertussis incidence: an interview with Leonard Friedland, M.D., V.P. and Director of Scientific Affairs and Public Health for GSK Vaccines

Distinguishing pertussis (also known as whooping cough) from other respiratory illnesses is challenging in particular among adults because the signs and symptoms of pertussis overlap with those of other respiratory diseases.

24 Oct 2013

Patient assistance programs help breast cancer patients to learn more about adjuvant therapy

Patient assistance programs can help breast cancer patients meet a variety of needs that can interfere with getting recommended adjuvant therapies such as radiation, chemotherapy, and hormonal treatments, according to a study published recently in the online edition of the Journal of Oncology Practice.

24 Oct 2013

Metformin could serve as radiosensitizer to treat patients with stage III non-small cell lung cancer

Treating aggressive lung cancer with the diabetes drug metformin along with radiation and chemotherapy may slow tumor growth and recurrence, suggests new preliminary findings from researchers at the Perelman School of Medicine at the University of Pennsylvania being presented during an oral abstract session October 28 at the 15th World Conference on Lung Cancer.

24 Oct 2013

A simple blood test may reveal the earliest signs of pancreatic cancer

Reporting on a small preliminary study, Johns Hopkins researchers say a simple blood test based on detection of tiny epigenetic alterations may reveal the earliest signs of pancreatic cancer, a disease that is nearly always fatal because it isn't usually discovered until it has spread to other parts of the body.

23 Oct 2013

Imugene Acquiring Biolife, As Lead Pipeline Candidate Nears Phase II

...

23 Oct 2013

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.

23 Oct 2013

Scientists reveal first comprehensive genomic analysis of aggressive lymphomas

Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.

23 Oct 2013

EORTC/GIMEMA trial shows combination of GO and chemotherapy provides no benefit for older patients with AML

Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.

23 Oct 2013

Stage and grade dominate RCC outcomes

Tumor grade and American Joint Committee on Cancer stage have emerged as the most important predictors of mortality in a competing risks analysis of patients undergoing nephrectomy for renal cell carcinoma.

22 Oct 2013

REGARD VEGF receptor-2 as gastric cancer target

Targeting vascular endothelial growth factor receptor-2 mediated signaling is an effective strategy against advanced gastric cancer, results from the REGARD trial demonstrate.

22 Oct 2013

Amgen Buys Roche Rights To Neutropenia Drugs

...

22 Oct 2013

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.

22 Oct 2013

Physicians rarely discuss risks of cancer screening with patients

A survey finds that most patients are not being told about the possibility of overdiagnosis and overtreatment as a result of cancer screenings, according to report in a research letter by Odette Wegwarth, Ph.D., and Gerd Gigerenzer, Ph.D., of the Max Planck Institute for Human Development, Berlin, Germany.

22 Oct 2013

Clinical trials will help to develop treatment and follow-up of COPD patients

Three major clinical trials will help to develop and target treatment and follow-up of patients suffering from COPD, lung cancer and rheumatoid arthritis in Norway.

22 Oct 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

Polaris Group reports positive results from ADI-PEG 20 Phase 2 trial for malignant pleural mesothelioma

Biodesix presents additional VeriStrat Phase III trial data at World Conference on Lung Cancer

Research: Neurotoxin provides more relief from pain in dogs with bone cancer

MIT researchers design stealth drug delivery system to attack TNBC cells

Diabetic patients may require higher doses of metformin to achieve same anti-cancer activity

"One-two punch" disables tumors' defenses

Pertussis incidence: an interview with Leonard Friedland, M.D., V.P. and Director of Scientific Affairs and Public Health for GSK Vaccines

Patient assistance programs help breast cancer patients to learn more about adjuvant therapy

Metformin could serve as radiosensitizer to treat patients with stage III non-small cell lung cancer

A simple blood test may reveal the earliest signs of pancreatic cancer

Imugene Acquiring Biolife, As Lead Pipeline Candidate Nears Phase II

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Scientists reveal first comprehensive genomic analysis of aggressive lymphomas

EORTC/GIMEMA trial shows combination of GO and chemotherapy provides no benefit for older patients with AML

Stage and grade dominate RCC outcomes

REGARD VEGF receptor-2 as gastric cancer target

Amgen Buys Roche Rights To Neutropenia Drugs

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

Physicians rarely discuss risks of cancer screening with patients

Clinical trials will help to develop treatment and follow-up of COPD patients

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in